http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2299231-C

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05ff905fdc49089f5f25746eaeb40190
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-21
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 1998-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2003-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4522bdd73a0ee75b703abbc407f6706
publicationDate 2003-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2299231-C
titleOfInvention Compressed nitroglycerin tablet and its method of manufacture
abstract The present invention is directed to a stable nitroglycerin containing pharmaceutical composition, preferably a tablet which is prepared by direct compression technology. The formulation closely replicates the properties of nitroglycerin molded sublingual tablets (e.g. adequate disintegration and sublingual absorption), while reducing the problems experienced with compressed tablets (e.g. friability and weight variations). The stable table ts are characterized by a decreased migration of nitroglycerin, decreased poten cy loss, excellent content uniformity when stored. The preferred combination of components are: nitroglycerin/lactose dilution, hydrous lactose, glyceril monostearate, fumed silica, pregelatinized starch and calcium stearate. The preferred process employs direct compression technology to yield composition showing adequate disintegration, bioavailability and improved stability.</SD OAB>
priorityDate 1997-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24699
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419514741
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707758
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453754419
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84571
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID440995
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474324
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15324
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4510
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553385
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496863
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555446
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322677
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448178750

Total number of triples: 35.